Antimicrobial Stewardship Protocols

Clinical Pathways and Guidance

Guidelines for Initial Therapy for Common Pediatrics Infections (PDF)

Antibiotic Prophylaxis in ECMO Patients: Cannulation in Sterile Setting and Cannulation in Non-Sterile Setting

Antibiotic-Loaded Bone Cement

Appendicitis Antibiotic Selection Guideline

Community Acquired Pneumonia

Drug-Susceptible Tuberculosis Therapy Guideline (PDF)

ENT Peri-Operative Antibiotic Prophylaxis Guidelines

Fever in Infants (8 to 21 days old) Pathway

Fever in Oncology Patients Pathway

Liver Transplant Post-Op Antimicrobial Selection and Duration

Neonatal and Young Infant (7-60 day) Urinary Tract Infection Pathway

NICU Late Onset Sepsis Algorithm

Palivizumab (Synagis®) Guideline

Pediatric Sepsis and Septic Shock Pathway

Prolonged Fever and Neutropenia Pathway

Skin and Soft Tissue Infections 

Surgical Prophylaxis Guidelines: LPCH Surgical Prophylaxis Guideline and ASHP Surgical Prophylaxis Guideline

Urinary Tract Infections

Antimicrobial Dosing and Monitoring

Antimicrobial Monitoring Guidelines

Amoxicillin-clavulanate (Augmentin®) Dosing Guide (PDF)

Azole Antifungal Therapeutic Drug Monitoring Guidance (PDF)

Housestaff Manual 

LPCH Blue Card – Antibiogram and Antimicrobial Dosing Quick Reference Card (PDF)

Pediatric Renal Antibiotic Dosing Recommendations (PDF)

Prolonged Infusion of Beta-Lactam Guidelines

Vancomycin per Pharmacy

Antibiotic Allergy

Antibiotic Desensitization Protocol

Antibiotic Graded Challenge Protocol

Allergy Clinical Decision Support Tool

– Antibiotic Allergy Clinical Decision Support Tool 
– Antibiotic Allergy Tool – Rationale Document 
Antibiotic Allergy Tool Instructions Powerpoint (PPTX)
– Video Tutorial 

Antimicrobial Restrictions

List of restricted antimicrobials at LPCH 

Restricted antimicrobial approval process

COVID-19 Resources

COVID-19 Inpatient Treatment Algorithm

Evusheld Monoclonal Antibody against SARS CoV-2 for Pre-Exposure Prophylaxis

LPCH Therapies for High-Risk Nonhospitalized Patients with Mild to Moderate COVID-19

Multisystem Inflammatory Syndrome in Children (MIS-C) Pathway